These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 3540826)

  • 1. Decreased baseline beta-lactamase production and inducibility associated with increased piperacillin susceptibility of Pseudomonas cepacia isolated from children with cystic fibrosis.
    Chiesa C; Labrozzi PH; Aronoff SC
    Pediatr Res; 1986 Nov; 20(11):1174-7. PubMed ID: 3540826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences in drug susceptibility between isolates of Pseudomonas cepacia recovered from patients with cystic fibrosis and other sources and its relationship to beta-lactamase focusing pattern.
    Aronoff SC; Labrozzi PH
    Pediatr Pulmonol; 1986; 2(6):368-72. PubMed ID: 3492701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of pH and CO2 on in vitro susceptibility of Pseudomonas cepacia to beta-lactams.
    Corkill JE; Deveney J; Pratt J; Shears P; Smyth A; Heaf D; Hart CA
    Pediatr Res; 1994 Mar; 35(3):299-302. PubMed ID: 7514780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "Switching Partners": Piperacillin-Avibactam Is a Highly Potent Combination against Multidrug-Resistant
    Zeiser ET; Becka SA; Wilson BM; Barnes MD; LiPuma JJ; Papp-Wallace KM
    J Clin Microbiol; 2019 Aug; 57(8):. PubMed ID: 31167848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Surveillance of Pseudomonas aeruginosa sensitivity to antibiotics in France and distribution of beta-lactam resistance mechanisms: 1998 GERPB study].
    Cavallo JD; Leblanc F; Fabre R
    Pathol Biol (Paris); 2000 Jun; 48(5):472-7. PubMed ID: 10949844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pseudomonas aeruginosa chromosomal beta-lactamase in patients with cystic fibrosis and chronic lung infection. Mechanism of antibiotic resistance and target of the humoral immune response.
    Ciofu O
    APMIS Suppl; 2003; (116):1-47. PubMed ID: 14692154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Derepressed beta-lactamase production as a mediator of high-level beta-lactam resistance in Pseudomonas cepacia.
    Aronoff SC
    Pediatr Pulmonol; 1988; 4(2):72-7. PubMed ID: 3260021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Mechanisms of resistance in Enterobacteriaceae towards beta-lactamase antibiotics].
    Susić E
    Acta Med Croatica; 2004; 58(4):307-12. PubMed ID: 15700687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-level beta-lactamase activity in sputum samples from cystic fibrosis patients during antipseudomonal treatment.
    Giwercman B; Meyer C; Lambert PA; Reinert C; Høiby N
    Antimicrob Agents Chemother; 1992 Jan; 36(1):71-6. PubMed ID: 1590704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activities of aztreonam, piperacillin, and ticarcillin combined with amikacin against amikacin-resistant Pseudomonas aeruginosa and P. cepacia isolates from children with cystic fibrosis.
    Aronoff SC; Klinger JD
    Antimicrob Agents Chemother; 1984 Feb; 25(2):279-80. PubMed ID: 6561954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of antibiotic resistance in Pseudomonas aeruginosa during two decades of antipseudomonal treatment at the Danish CF Center.
    Ciofu O; Giwercman B; Pedersen SS; Høiby N
    APMIS; 1994 Sep; 102(9):674-80. PubMed ID: 7946270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. beta-Lactamase Id of ceftazidime-resistant Pseudomonas aeruginosa strains.
    Michel-Briand Y; Nicolas T; Godard C; Plesiat P
    Microbiologica; 1992 Jan; 15(1):65-9. PubMed ID: 1556960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Sensitivity of Pseudomonas aeruginosa to beta-lactam antibiotics and effects of beta-lactamases].
    Avril JL; Cayla AM; Guist'hau O; Moillo-Batt A
    Pathol Biol (Paris); 1983 Jun; 31(6):471-5. PubMed ID: 6410345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
    Sader HS; Tosin I; Sejas L; Miranda E
    Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study of in vitro selected resistance of Pseudomonas aeruginosa to cefoperazone, ceftazidime, azthreonam and imipenem.
    Van der Auwera P; Husson M; Bulliard G
    Drugs Exp Clin Res; 1986; 12(11):871-83. PubMed ID: 3102194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of doripenem against Pseudomonas aeruginosa and Burkholderia cepacia isolates from both cystic fibrosis and non-cystic fibrosis patients.
    Traczewski MM; Brown SD
    Antimicrob Agents Chemother; 2006 Feb; 50(2):819-21. PubMed ID: 16436756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selection and properties of Pseudomonas aeruginosa variants resistant to beta-lactam antibiotics.
    Cullman W; Büscher KH; Dick W
    Eur J Clin Microbiol; 1987 Aug; 6(4):467-73. PubMed ID: 3117536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pseudomonas aeruginosa beta-lactamase as a defence against azlocillin, mezlocillin and piperacillin.
    Jacobs JY; Livermore DM; Davy KW
    J Antimicrob Chemother; 1984 Sep; 14(3):221-9. PubMed ID: 6436226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ceftazidime monotherapy vs. combined therapy in Pseudomonas pulmonary infections in cystic fibrosis.
    Padoan R; Cambisano W; Costantini D; Crossignani RM; Danza ML; Trezzi G; Giunta A
    Pediatr Infect Dis J; 1987 Jul; 6(7):648-53. PubMed ID: 3302917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolutionary diversification of Pseudomonas aeruginosa in an artificial sputum model.
    Davies EV; James CE; Brockhurst MA; Winstanley C
    BMC Microbiol; 2017 Jan; 17(1):3. PubMed ID: 28056789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.